血清结肠癌特异性抗原-2检测在结直肠癌随访和预后判断中的应用

Application of serum colon cancer-specific antigen-2 in postoperative follow-up and prognostic judgment of colorectal cancer

摘要:

目的：评估血清结肠癌特异性抗原-2（colon cancer-specific antigen-2，CCSA-2）检测在结直肠癌（colorectal cancer，CRC）术后随访监测和预后判断中的价值。方法：收集49例CRC住院患者（含结肠癌14例、直肠癌35例）术前3 d、术后7 d的血液样本各3 ml，酶联免疫吸附法测定其中CCSA-2的含量。术后每3~6月检测血清CCSA-2含量1次，观察其含量变化与肿瘤复发转移之间的关系。结果：术后第7天CRC患者血清中CCSA-2的含量明显较术前降低（t=26.53，P<0.001）。肿瘤复发转移后其血清CCSA-2的含量再次升高，高于术后第7天水平（P<0.01）。发生了复发转移者的术前血清CCSA-2含量明显高于未发生复发转移者的术前含量（t=4.94，P<0.001）。结论：血清CCSA-2有望成为CRC患者术后随访的一个有用的监测指标，同时也有望成为判断CRC患者预后的一个血清标志物。

Abstract:

Objective：To evaluate the value of serum colon cancer-specific antigen-2（CCSA-2） as a surveillance and prognostic mark－er for colorectal cancer（CRC）. Methods：CCSA-2 content in the serum was measured using ELISA method from 49 CRC patients（in－cluding 14 colon cancer patients and 35 rectal cancer patients） on 3 d before surgery and on 7 d after surgery，respectively. Serum CCSA-2 level was also detected every 3-6 months during the follow-up to observe the relationship between CCSA-2 level and tu－mor recurrence and metastasis. Results：Serum CCSA-2 content in CRC patients was significantly decreased on 7 d after surgery（t=26.53，P<0.001），but it was rebounded to a high level again when the recurrence occurred（P<0.01）. Pre-operative serum CCSA-2 level in patients with recurrence after surgery was significantly higher than that in the patients without recurrence. Conclusion：Serum CCSA-2 may be a useful biomarker in surveillance and prognosis estimate for CRC.